Cancer Clinical Trial
— TeleSPCOfficial title:
The Effect of Specialized Palliative Telemedicine for Patients With Advanced Cancer at Home
NCT number | NCT05231070 |
Other study ID # | R315A18018 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | December 1, 2022 |
Est. completion date | May 2024 |
Specialized palliative care (SPC) plays an important role in providing patient-centered care and support to informal caregiver, besides establishing/intensifying/coordinating collaboration with primary and secondary health care sectors (hospital nurse/district nurse and general practitioner/oncologist) to improve care and support for patients and burdened informal caregiver. This study proposes to develop a SPC intervention enriched with a dyadic psychological intervention for patients with advanced cancer and their informal caregiver delivered by telemedicine at home (TeleSPC). It is our hypothesis that the intervention can enhance patient-centered care at home, support their informal caregiver, and improve relations/integration between the SPC teams, oncologic teams, the general practitioners and district nurses.
Status | Recruiting |
Enrollment | 348 |
Est. completion date | May 2024 |
Est. primary completion date | May 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Patient inclusion criteria: - adults (at least 18 years old) - solid organ cancer - no longer receives curativ treatment - provide written informed consent - are able to speak and understand Danish Language - are cognitively able to participate in the study - have at least one symptom or problem with score = 3 at the EORTC QLQ-C30 Patient exclusion criteria: - primary brain cancer or central nervous system metastases - a prognosis of less than six months - incapable of cooperating in the trial - already receive SPC Informal caregiver inclusion criteria: - adults (at least 18 years old) - indicated by the patient as the closest informal caregiver - able to speak and understand danish langues - provide written informed consent Informal caregiver exclusion criteria: - refuse to participate in the study |
Country | Name | City | State |
---|---|---|---|
Denmark | Rigshospitalet | København | København Ø. |
Lead Sponsor | Collaborator |
---|---|
Rigshospitalet, Denmark | Danish Cancer Society |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline patient's health-related quality of life at 2 weeks, 4 weeks, 8 weeks, and 6 months | The European Organisation for Research and Treatment of Cancer Quality of life Questionnaire - Core 30 (EORTC QLQ-C30) to assess several physical and psychosocial aspects of the patient's health-related quality of life. Scores range from 0 to 100; high values in the functioning and quality of life scales and low values in the symptoms scales indicate better outcomes. | Baseline, 2 weeks, 4 weeks, 8 weeks, and 6 months | |
Secondary | Change from baseline patients' use of health care system at 6 months | Clinical information collected from patients' records regarding number of hospitalizations, days spent in hospital, and date of death | Baseline and 6 months | |
Secondary | Change from baseline patients and informal caregiver dyadic coping at 4 weeks, 8 weeks, and 6 months | Dyadic Coping inventory to assess how patients and informal caregiver manage stress together concerning decision making and giving support to each other. Four subscales were selected to evaluate dyadic coping (dyad patient and relative/caregiver) regarding stress communicated by oneself (max. score 20), stress communication of the partner (max. score 20), common dyadic coping (max. score 25), and evaluation of dyadic coping (max score 10). Higher scores denote greater levels of the constructs measured by each subscale. | Baseline, 4 weeks, 8 weeks, and 6 months | |
Secondary | Change from baseline caregiver burden at 4 weeks, 8 weeks, and 6 months | Zarit Burden Interview to measure subjective burden among caregivers. Sum of scores ranges from 0 to 88. A score of 17 or more is considered high burden. | Baseline, 4 weeks, 8 weeks, and 6 months | |
Secondary | Change from baseline informal caregiver health related quality of life at 4 weeks, 8 weeks, and 6 months | RAND 36-Item Short Form Health Survey version 1.0. Scores range from 0 to 100; a higher score indicates a better result. | Baseline, 4 weeks, 8 weeks, and 6 months | |
Secondary | Healthcare professionals' satisfaction with intervention at 6 months | Interview with healthcare providers | 6 months | |
Secondary | Change from baseline patients' sleep at 2 weeks, 4 weeks, 8 weeks, and 6 months | Pittsburg Sleep Quality Index to determining the quality and patterns of sleep. Global score ranges from 0 to 21; 0 indicates no difficult and 21 indicates severe difficlties in all areas. | Baseline, 2 weeks, 4 weeks, 8 weeks, and 6 months | |
Secondary | Change from baseline patients' anxiety at 2 weeks, 4 weeks, 8 weeks, and 6 months | Hospital anxiety and depression scale. Scores range from 0 to 21; 0-7 represent non-cases, 8-10 represent doubtful cases, and 11-21 represent definite cases. | Baseline, 2 weeks, 4 weeks, 8 weeks, and 6 months | |
Secondary | Change from baseline patient's depression at 2 weeks, 4 weeks, 8 weeks, and 6 months | Hospital anxiety and depression scale. Scores range from 0 to 21; 0-7 represent non-cases, 8-10 represent doubtful cases, and 11-21 represent definite cases. | Baseline, 2 weeks, 4 weeks, 8 weeks, and 6 months | |
Secondary | Patients and informal caregivers' satisfaction with intervention at 6 months | Patients and informal caregivers will be requested to rate their satisfaction (scale 1-5), and will have the possibility to write any comment | 6 months | |
Secondary | Change from baseline informal caregivers' anxiety at 4 weeks, 8 weeks, and 6 months | Patient Health Questionnaires' scales (GAD-7). Seven items, each of which is scored 0 to 3, providing a 0 to 21 severity score. | Baseline, 4 weeks, 8 weeks, and 6 months | |
Secondary | Change from baseline informal caregivers' depression at 4 weeks, 8 weeks, and 6 months | Patient Health Questionnaires' scales (PHQ). Nine items, each of which is scored 0 to 3, providing a 0 to 27 severity score. | Baseline, 4 weeks, 8 weeks, and 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|